Company Insights

ARCT supplier relationships

Explore interactive graphBrowse insights index
ARCT supplier relationship map

Arcturus Therapeutics (ARCT): Supplier map and what it means for investors

Arcturus Therapeutics is a clinical-stage mRNA therapeutics company that monetizes through development-stage partnerships, licensing of its mRNA and lipid nanoparticle technologies, and the prospect of future product sales if candidates progress to approval and commercialization. The firm outsources the vast majority of its manufacturing and many development functions to third-party contract development and manufacturing organizations (CDMOs) and engages capital markets and advisors to underwrite and communicate financing events. For investors evaluating supplier risk, the relevant signal is simple: Arcturus runs a capital-light, outsourced operational model that concentrates execution risk in a small set of critical manufacturing and advisory partners.

Explore supplier risk dashboards and relationship analysis at https://nullexposure.com/ for deeper diligence.

How Arcturus operates and where revenue will come from

Arcturus is an RNA drug developer focused on liver and respiratory indications. Revenue today comes from R&D collaborations, grants, and one-off commercial arrangements; true recurring revenue will depend on successfully moving candidates through clinical trials to regulatory approval and commercialization. The company derives operational leverage by licensing its mRNA platform and outsourcing GMP production to specialized CDMOs rather than building large in-house manufacturing capacity. That posture reduces fixed-cost investment but concentrates supply-chain and quality risk with its external partners.

The supplier and advisor roll call (what’s on record)

Below is every entity referenced in the source materials, with a concise plain-English description and the source for that mention.

Citigroup

Citigroup acted as a joint book-running manager for Arcturus’ public offering. The role confirms Citigroup’s involvement in the company’s capital markets execution during FY2020 (GlobeNewswire, July 31, 2020).

Guggenheim Securities

Guggenheim Securities served as a joint book-runner on the same FY2020 offering, participating in underwriting and distribution of newly issued shares (GlobeNewswire, July 31, 2020).

Barclays

Barclays was named as a joint book-running manager for the July 2020 offering, supporting the company’s equity raise and distribution to institutional investors (GlobeNewswire, July 31, 2020).

H.C. Wainwright & Co.

H.C. Wainwright was listed as a co-lead manager for the FY2020 offering, reflecting its role in structuring and marketing the transaction (GlobeNewswire, July 31, 2020).

Baird

Baird acted as a co-lead manager in the FY2020 offering, demonstrating participation from regional investment banks in Arcturus’ financing strategy (GlobeNewswire, July 31, 2020).

B. Riley FBR

B. Riley FBR served as a co-lead manager on the FY2020 equity offering, contributing to the syndicate that placed new shares (GlobeNewswire, July 31, 2020).

Ladenburg Thalmann

Ladenburg Thalmann participated as a co-manager for the 2020 offering, indicating the syndicate included a range of boutique and mid-market underwriters (GlobeNewswire, July 31, 2020).

Catalent, Inc.

Catalent entered a partnership with Arcturus in May 2020 to support manufacture of the company’s COVID-19 mRNA vaccine candidate (LUNAR-COV19), establishing Catalent as a key CDMO for process scale-up and GMP supply (GlobeNewswire, May 4, 2020).

Vinson & Elkins L.L.P.

Vinson & Elkins was engaged as legal counsel for Arcturus in a 2018 shareholder litigation matter, showing the company’s use of external law firms for corporate disputes (GlobeNewswire, March 28, 2018).

MORROW SODALI

MORROW SODALI was listed as Arcturus’ proxy solicitor in the 2018 corporate filing and investor communication regarding shareholder matters (GlobeNewswire, March 28, 2018).

LifeSci Advisors LLC

LifeSci Advisors is identified as an investor relations contact for Arcturus in the 2018 press release, reflecting outsourced IR support to manage public markets messaging (GlobeNewswire, March 28, 2018).

Joele Frank, Wilkinson Brimmer Katcher

Joele Frank was listed among media contacts for Arcturus in the 2018 press release, evidencing retained external public affairs and media relations capability (GlobeNewswire, March 28, 2018).

株式会社ARCALIS (Arcalis)

Arcalis (Japan) licensed Arcturus’ mRNA manufacturing technology and planned to serve as a regional CDMO partner, targeting cGMP mRNA production to support Arcturus’ R&D, clinical and potential commercial supply in Japan and Asia (JETRO, 2022).

What these relationships reveal about Arcturus’ operational profile

  • Contracting posture — outsourced and specialist-dependent. Arcturus deliberately leverages external CDMOs (Catalent, Arcalis and others referenced in company materials) for drug substance and finished product manufacture rather than vertical integration. This reduces capital intensity and favors flexible capacity scaling, but it transfers operational criticality downstream.
  • Concentration and criticality — a small set of suppliers matter. The company’s own disclosures describe manufacturing supply as critical: inability to source materials or manufacturing capacity would materially delay trials and commercialization. The named CDMO partners and licensees underscore this concentration risk at scale.
  • Advisory and capital-market relationships — diverse syndicate and retained communications firms. A syndicate of investment banks (Citigroup, Guggenheim, Barclays, H.C. Wainwright, Baird, B. Riley FBR, Ladenburg) handled FY2020 equity issuance, while external PR, IR, legal, and proxy firms (Joele Frank, LifeSci Advisors, Vinson & Elkins, MORROW SODALI) provide corporate governance and market-facing services. These relationships indicate institutional access to financing and a professionalized external communications strategy.
  • Maturity of supplier network — CDMO partners with cGMP ambitions. The Arcalis licensing (JETRO, 2022) and Catalent manufacturing partnership (GlobeNewswire, May 2020) indicate that Arcturus is moving from lab-scale to regulated GMP supply via partners rather than in-house buildout, accelerating potential commercial readiness if clinical success follows.

Explore a full supplier risk scorecard for Arcturus at https://nullexposure.com/ to prioritize due diligence.

Investment implications and risk checklist

  • Operational risk is supply-chain risk. Clinical timelines and future revenue hinge on a small number of external manufacturers and raw-material suppliers sourced globally; management’s disclosures label that supply continuity as critical.
  • Capital access is established but episodic. The 2020 underwriter syndicate shows the company can access public equity markets with bank support, but continued dilution or financing-dependent execution is a live investment variable.
  • Execution levers are external. Successful commercialization will require not just clinical data but flawless external manufacturing scale-up and regulatory-compliant supply chains managed by partners.

Key takeaways:

  • Arcturus runs an outsourced manufacturing model with concentrated supplier risk.
  • CDMO partners such as Catalent and Arcalis are operationally critical to timelines and quality.
  • A broad underwriting and advisor network supports capital and communications but does not eliminate manufacturing dependency.

For a focused supplier risk breakdown and to monitor changes in Arcturus’ partner roster, visit https://nullexposure.com/.

Assess supplier contracts, certificate-of-analysis practices, and alternative-source strategies as part of your next diligence steps; external relationships determine Arcturus’ path to revenue as much as clinical success.